Keyphrases
Antischistosomal
66%
Hydantoin
66%
Aryl
66%
Androgen Receptor
66%
Schistosomiasis
35%
Orally Active
31%
Heterocycles
23%
Antischistosomal Drugs
19%
Receptor Binding
19%
Integrated Control Programs
18%
Receptor Binding Affinity
15%
Parasite Stages
15%
Novel Mechanism of Action
15%
Tropical Parasitic Diseases
11%
Curb
11%
Lead Optimization
11%
Multidrug-resistant
11%
Chemotherapy
11%
Androgen Receptor Antagonist
7%
Endemic Countries
7%
Antiandrogen
7%
Schistosomicidal Activity
7%
Cytotoxicity
7%
Functional Groups
7%
Structural Analogues
7%
Structural Requirements
7%
Schistosoma Mansoni
7%
Resistance Development
7%
Nilutamide
7%
Compound Design
7%
Structural Diversity
7%
Expected Outcomes
7%
Receptor-ligand Binding
7%
Specific Intent
7%
Receptor-ligand Interaction
7%
Binding Interaction
7%
New Drugs
7%
Last Resort
7%
Substructure
7%
Binding Studies
7%
Praziquantel
7%
Receptor Antagonism
7%
Fluke
7%
Diversity-guided
7%
Schistosoma
7%
Scale Usage
7%
SAR Data
7%
Public Health
7%
Pharmacology, Toxicology and Pharmaceutical Science
Hydantoin Derivative
100%
Androgen Receptor
100%
Schistosomiasis
53%
Lead Compound
23%
Side Effect
23%
Parasitosis
18%
Chemotherapy
18%
Schistosoma
11%
Functional Groups
11%
Hydantoin
11%
Androgen Receptor Antagonist
11%
Nilutamide
11%
Trematode
11%
Cytotoxicity
11%
Infection
11%
Structure Activity Relationship
11%
Praziquantel
11%
Medicine and Dentistry
Hydantoin Derivative
100%
Androgen Receptor
66%
Receptor Binding
35%
Schistosomiasis
35%
Binding Affinity
15%
Single Drug Dose
15%
Side Effect
15%
Parasite (Microbiology)
15%
Fluke
11%
Nilutamide
11%
Androgen Receptor Antagonist
11%
Parasitic Disease
11%
Cytotoxicity
7%
Schistosoma
7%
Ligand Binding
7%
Functional Groups
7%
Hydantoin
7%
Infection
7%
Praziquantel
7%